Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

aTYR PHARMA INC

ATYR · Nasdaq · CIK 0001339970 · Healthcare · Biotechnology

INSIDER SIGNAL

43.2 / 100

1 buyers · 1 purchase transaction lines · $50.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+5.3 / 25
Role+20.0 / 20
Recency+0.9 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
SCHIMMEL PAULDirector
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: SCHIMMEL PAUL · $50.0K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-27–2026-05-27

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

43.2 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 43.4
  2. 43.3
  3. 43.3
  4. 43.2
  5. 43.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
3Sales
3Other Form 4 lines
4SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-43.0%
3M
-51.2%
6M
-70.4%
12M
-75.4%

Volatility & liquidity

Volatility
115.5%
Beta
—
Avg daily value
USD 805,673

Valuation

Market cap
USD 24.1M
P/E
—

Fundamentals

Profit margin
—
ROE
-109.8%
Industry
Biotechnology

Market data

Price data up to: 2026-10-09 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
12,893,008
Previous report
10,668,157
Avg daily volume
13,422,383
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-27SCHIMMEL PAULPurchase (P)Common Stock100,000USD 0.50USD 50,000SEC filing ↗
2025-10-09SCHIMMEL PAULPurchase (P)Common Stock317,999USD 0.94USD 298,919SEC filing ↗
2025-10-08SCHIMMEL PAULPurchase (P)Common Stock682,001USD 0.90USD 613,801SEC filing ↗
2025-03-17Gross Jane APurchase (P)Common Stock3,750USD 4.00USD 15,000SEC filing ↗
2024-07-24SCHIMMEL PAULPurchase (P)Common Stock52,300USD 1.93USD 100,939SEC filing ↗
2024-07-23SCHIMMEL PAULPurchase (P)Common Stock6,648USD 1.82USD 12,099SEC filing ↗
2024-07-22SCHIMMEL PAULPurchase (P)Common Stock41,052USD 1.74USD 71,430SEC filing ↗
2024-06-05DENYES NANCYPurchase (P)Common Stock5,000USD 1.86USD 9,300SEC filing ↗
2024-05-31Shukla SanjayPurchase (P)Common Stock20,000USD 1.81USD 36,200SEC filing ↗
2024-05-31Broadfoot Jill MariePurchase (P)Common Stock5,000USD 1.79USD 8,950SEC filing ↗
2024-05-30COUGHLIN TIMOTHYPurchase (P)Common Stock50,000USD 1.75USD 87,500SEC filing ↗
2023-12-12Shukla SanjayPurchase (P)Common Stock12,000USD 1.18USD 14,160SEC filing ↗
2023-12-11Shukla SanjayPurchase (P)Common Stock3,000USD 1.17USD 3,510SEC filing ↗
2023-11-13Shukla SanjayPurchase (P)Common Stock13,578USD 1.11USD 15,072SEC filing ↗
2023-11-10Shukla SanjayPurchase (P)Common Stock1,422USD 1.14USD 1,621SEC filing ↗

Form 4 evidence

7 transaction lines in the latest 365-day window; 71 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-27SCHIMMEL PAULPurchase (P)Common Stock100,000USD 0.50USD 50,000SEC filing ↗
2026-02-04Shukla SanjaySale (S)Common Stock3,745USD 0.98USD 3,670SEC filing ↗
2026-02-04DENYES NANCYSale (S)Common Stock1,118USD 0.98USD 1,096SEC filing ↗
Show recent Form 4 evidence (7 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-27SCHIMMEL PAULPurchase (P)Common Stock100,000USD 0.50USD 50,000SEC filing ↗
2026-02-04Shukla SanjaySale (S)Common Stock3,745USD 0.98USD 3,670SEC filing ↗
2026-02-04DENYES NANCYSale (S)Common Stock1,118USD 0.98USD 1,096SEC filing ↗
2026-02-04Broadfoot Jill MarieSale (S)Common Stock1,558USD 0.98USD 1,527SEC filing ↗
2026-02-03Shukla SanjayOption exercise / conversion (M)Common Stock10,375USD —USD —SEC filing ↗
2026-02-03DENYES NANCYOption exercise / conversion (M)Common Stock2,687USD —USD —SEC filing ↗
2026-02-03Broadfoot Jill MarieOption exercise / conversion (M)Common Stock3,750USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerATYR
CIK0001339970
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history71 transaction lines from 2020-02-06 to 2026-05-27
28 P purchase lines · 18 S sale lines · 25 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.